Dr. Ulmann is Chairman of HRA Pharma, a company that he created in 1996 and managed until 2009. Under his leadership, HRA Pharma developed into a pharmaceutical leader in contraception and orphan diseases. Previously, Andre Ulmann served as Medical Director and Head of Clinical Research for Roussel-Uclaf and HMR (later Sanofi-Aventis) with global responsibility in endocrinology, immunology, neurobiology, and bone diseases. Andre Ulmann holds an M.D. degree from the University of Paris VII and a Ph.D. from the University of Paris VI, France.